Notwithstanding promising clinical evidence, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing substantial resistance from PBMs. These insurers are frequently https://geraldjlsa288321.blog-eye.com/42369787/the-medication-faces-is-meeting-pharmacy-benefit-manager-hurdles-a-look-at-reimbursement-battles